BDX:NYSEBecton, Dickinson and Company Analysis

Becton, Dickinson (BDX) is trading at $165.46, comfortably above its 200‑day SMA (150) but below the 20‑day SMA (176), indicating a medium‑term bullish bias while short‑term momentum is weakening. The RSI of 39 and a bearish MACD histogram suggest the stock is approaching oversold territory, offering a potential entry point. Fundamentals show a trailing P/E of 27 versus an industry average of 25, hinting at modest overvaluation, yet a forward P/E of 12 reflects strong earnings growth expectations. The company delivered Q1 earnings of $2.91 per share, beating consensus, and analysts have lifted the price target to $198, implying ~19% upside from current levels. Dividend sustainability appears reasonable with a 2.54% yield and a 68% payout ratio supported by solid operating cash flow, though the debt‑to‑equity ratio of 77% warrants monitoring. Volatility is elevated at ~30% over the past 30 days, but a beta of 0.6 indicates lower systematic risk. Regulatory exposure is medium, given reliance on FDA clearances, while geographic concentration in the U.S. keeps currency and geopolitical risk low. Overall, the blend of a resilient dividend, growth‑oriented earnings outlook, and technical oversold signals makes BDX an attractive candidate for investors with a medium‑to‑long‑term horizon.